NCT02966548View on ClinicalTrials.gov

Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

January 4, 2017

Primary Completion Date

July 9, 2024

Study Completion Date

July 9, 2024

Conditions
Cancer
Interventions
DRUG

Relatlimab

Specified dose on specified days

DRUG

Nivolumab

Specified dose on specified days

Trial Locations (1)

2778577

Local Institution - 0001, Kashiwa-shi

Sponsors
All Listed Sponsors
collaborator

Ono Pharmaceutical Co. Ltd

INDUSTRY

lead

Bristol-Myers Squibb

INDUSTRY

NCT02966548 - Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter